Yi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Liu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Yuguo Du
Chinese Academy of Sciences
7 shared publications Huili Liu
Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education Yantai University Yantai China
5 shared publications- Jun Liu
State Key Laboratory of Environmental Chemistry and Eco-Toxicology, Research Center for Eco-Environmental Sciences
5 shared publications Yuguo Du
Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China
5 shared publicationsHongbo Wang
Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education Yantai University Yantai China
3 shared publications- Hongbo Wang
Space Information Research Institute and Zhejiang Key Laboratory of Space Information Sensing and Transmission, Hangzhou Dianzi University, Hangzhou, China
3 shared publications
Latest Publications
- 12 May 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (5) , e71317
Discovery of Bistratamides as Efficacious Reversers of P‐Glycoprotein‐Mediated Multidrug Resistance
Although strategies combining multidrug resistance (MDR) reversal agents with chemotherapeutic drugs have demonstrated efficacy in clinical practice, their widespread application remains limited by potential toxicity. Natural thiazole‐containing macrocycles have displayed promising MDR reversal potential. However, the 18‐membered macrocycles bistratamides, despite their structural similarity to the known MDR reversal agent dendroamide A, remain unexplored regarding potential roles as MDR reversal agents and their molecular targets. In this study, we report the synthesis and initial discovery of bistratamides as potential MDR reversal agents. Structure–activity relationship analysis revealed that the oxazoline or oxazole motifs embedded within the macrocyclic framework are essential for MDR reversal activity in bistratamides. The oxazoline‐containing bistratamide derivative 15 demonstrated the greatest synergistic anticancer effect among the examined compounds, exhibiting > three‐fold greater activity than verapamil (VRP) with no observable toxicity in KBV cells and normal human podocytes. The MDR reversal effect of 15 in combination with paclitaxel was further validated through combination assays and flow cytometry. Subsequent rhodamine 123 (Rh123) accumulation assays and western blotting confirmed that 15 exerts its MDR reversal activity by inhibiting P‐gp efflux function rather than affecting its expression. Our findings suggest that 15 represents a promising starting point for the development of novel chemosensitizing agents.
- 12 May 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (5) , e71317
Discovery of Bistratamides as Efficacious Reversers of P‐Glycoprotein‐Mediated Multidrug Resistance
Although strategies combining multidrug resistance (MDR) reversal agents with chemotherapeutic drugs have demonstrated efficacy in clinical practice, their widespread application remains limited by potential toxicity. Natural thiazole‐containing macrocycles have displayed promising MDR reversal potential. However, the 18‐membered macrocycles bistratamides, despite their structural similarity to the known MDR reversal agent dendroamide A, remain unexplored regarding potential roles as MDR reversal agents and their molecular targets. In this study, we report the synthesis and initial discovery of bistratamides as potential MDR reversal agents. Structure–activity relationship analysis revealed that the oxazoline or oxazole motifs embedded within the macrocyclic framework are essential for MDR reversal activity in bistratamides. The oxazoline‐containing bistratamide derivative 15 demonstrated the greatest synergistic anticancer effect among the examined compounds, exhibiting > three‐fold greater activity than verapamil (VRP) with no observable toxicity in KBV cells and normal human podocytes. The MDR reversal effect of 15 in combination with paclitaxel was further validated through combination assays and flow cytometry. Subsequent rhodamine 123 (Rh123) accumulation assays and western blotting confirmed that 15 exerts its MDR reversal activity by inhibiting P‐gp efflux function rather than affecting its expression. Our findings suggest that 15 represents a promising starting point for the development of novel chemosensitizing agents.
- 17 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 134, 118522
Discovery of valine thiazole-containing derivatives as potent reversers of P-glycoprotein–mediated multidrug resistance
- 17 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 134, 118522
Discovery of valine thiazole-containing derivatives as potent reversers of P-glycoprotein–mediated multidrug resistance
- 15 November 2024
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 26 (47) , 10090-10095
Efforts toward the Total Synthesis of Thuggacin A
Thuggacin A (1) is a 17-membered-ring-polyketide antibiotic compound with excellent antituberculosis activity. The total synthesis of thuggacin A has not yet been reported so far. Herein, we disclose our efforts toward the convergent total synthesis of thuggacin A. The key synthetic features include our own one-pot cascade thiazole formation, Evans syn-aldol, Mukaiyama asymmetric aldol reaction, organosilicon-promoted selective alkyne reduction, Shiina macrolactonization, and a nucleophilic ring-opening of epoxide with alkyne to assemble the main framework of thuggacin A. The enantioselective synthesis of trimethylsilyl ethoxymethyl (SEM) derived thuggacin A analogue 2 was achieved in 18 longest linear steps with 2.0% overall yield, and the bioassay of 2 exhibited moderate antituberculosis activity with minimum inhibitory concentration (MIC) of 320 mu g/mL.
- 15 November 2024
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 26 (47) , 10090-10095
Efforts toward the Total Synthesis of Thuggacin A
Thuggacin A (1) is a 17-membered-ring-polyketide antibiotic compound with excellent antituberculosis activity. The total synthesis of thuggacin A has not yet been reported so far. Herein, we disclose our efforts toward the convergent total synthesis of thuggacin A. The key synthetic features include our own one-pot cascade thiazole formation, Evans syn-aldol, Mukaiyama asymmetric aldol reaction, organosilicon-promoted selective alkyne reduction, Shiina macrolactonization, and a nucleophilic ring-opening of epoxide with alkyne to assemble the main framework of thuggacin A. The enantioselective synthesis of trimethylsilyl ethoxymethyl (SEM) derived thuggacin A analogue 2 was achieved in 18 longest linear steps with 2.0% overall yield, and the bioassay of 2 exhibited moderate antituberculosis activity with minimum inhibitory concentration (MIC) of 320 mu g/mL.
- Open Access
- 1 November 2024
- Published by MDPI AG in Marine Drugs
- Vol. 22 (11) , 494
Design, Synthesis, and Evaluation of Novel Thiazole-Containing Algicides Inspired by Bacillamide A
The pursuit of highly effective, low-toxicity, and eco-friendly algicides for controlling and eradicating harmful algal blooms (HABs) is of paramount importance. The natural allelochemical bacillamide A has displayed impressive algicidal activity against harmful algae with favorable safety profiles. However, the poor synthetic efficiency and large dose requirements of bacillamide A limit its further application. In this paper, 17 thiazole-containing bacillamide derivatives (BDs) were designed and synthesized in three linear steps as potential algicides. Eight compounds (6a, 6c, 6j, 7b, 7c, 7d, 7e, and 7g) displayed potent inhibitory effects against Prorocentrum minimum, Skeletonema costatum, and Alexandrium pacificum, and they had similar or better activity than the positive control (CuSO4) and bacillamide A. Compound 6a exhibited the most potent algicidal activity against S. costatum (half-maximal effective concentration [EC50] = 0.11 μg/mL), being 23-fold more potent than bacillamide A, 28-fold more potent than CuSO4, and 39-fold more potent than Diuron. Compound 6j exhibited significant algicidal activity against the toxic dinoflagellates P. minimum (EC50 = 1.0 μg/mL) and A. pacificum (EC50 = 0.47 μg/mL), being 3–5-fold more potent than natural bacillamide A, Diuron, and CuSO4. Micrographs and SEM images revealed that 6j induced cell wall rupture and cellular content leakage. Biochemical and physiological studies indicated that 6j might partially disrupt the antioxidant and photosynthetic systems in algal cells, resulting in morphological changes, cell wall rupture, and inclusion leakage. Our work suggests that 6j has a distinct mode of action from CuSO4 and provides a promising candidate for the development of new algicides, worthy of further investigation.
- 1 November 2024
- Published by MDPI AG in Marine Drugs
- Vol. 22 (11) , 494
Open AccessDesign, Synthesis, and Evaluation of Novel Thiazole-Containing Algicides Inspired by Bacillamide A
The pursuit of highly effective, low-toxicity, and eco-friendly algicides for controlling and eradicating harmful algal blooms (HABs) is of paramount importance. The natural allelochemical bacillamide A has displayed impressive algicidal activity against harmful algae with favorable safety profiles. However, the poor synthetic efficiency and large dose requirements of bacillamide A limit its further application. In this paper, 17 thiazole-containing bacillamide derivatives (BDs) were designed and synthesized in three linear steps as potential algicides. Eight compounds (6a, 6c, 6j, 7b, 7c, 7d, 7e, and 7g) displayed potent inhibitory effects against Prorocentrum minimum, Skeletonema costatum, and Alexandrium pacificum, and they had similar or better activity than the positive control (CuSO4) and bacillamide A. Compound 6a exhibited the most potent algicidal activity against S. costatum (half-maximal effective concentration [EC50] = 0.11 μg/mL), being 23-fold more potent than bacillamide A, 28-fold more potent than CuSO4, and 39-fold more potent than Diuron. Compound 6j exhibited significant algicidal activity against the toxic dinoflagellates P. minimum (EC50 = 1.0 μg/mL) and A. pacificum (EC50 = 0.47 μg/mL), being 3–5-fold more potent than natural bacillamide A, Diuron, and CuSO4. Micrographs and SEM images revealed that 6j induced cell wall rupture and cellular content leakage. Biochemical and physiological studies indicated that 6j might partially disrupt the antioxidant and photosynthetic systems in algal cells, resulting in morphological changes, cell wall rupture, and inclusion leakage. Our work suggests that 6j has a distinct mode of action from CuSO4 and provides a promising candidate for the development of new algicides, worthy of further investigation.
- 29 May 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 144
Concise synthesis of the C15–C25 fragment of Thuggacins A-C
- 29 May 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 144
Concise synthesis of the C15–C25 fragment of Thuggacins A-C
- Open Access
Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme
Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator XI-011 analogs were designed, synthesized, and evaluated for their cytotoxic effects. Five compounds (13d, 13e, 14a, 14b, and 14n) exhibited good anti-glioma activity against U87 cells, with IC50 values lower than 2 μM. Notably, 13e showed the best anti-glioma activity, with an IC50 value up to 0.53 μM, providing a promising lead compound for new anti-glioma drug development. Mechanistic analyses showed that 13e suppressed the MDM4 protein expression, upregulated the p53 protein level, and induced cell cycle arrest at G2/M phase and apoptosis based on Western blot and flow cytometry assays.
Open AccessNovel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme
Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator XI-011 analogs were designed, synthesized, and evaluated for their cytotoxic effects. Five compounds (13d, 13e, 14a, 14b, and 14n) exhibited good anti-glioma activity against U87 cells, with IC50 values lower than 2 μM. Notably, 13e showed the best anti-glioma activity, with an IC50 value up to 0.53 μM, providing a promising lead compound for new anti-glioma drug development. Mechanistic analyses showed that 13e suppressed the MDM4 protein expression, upregulated the p53 protein level, and induced cell cycle arrest at G2/M phase and apoptosis based on Western blot and flow cytometry assays.
- 14 January 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 136
Convenient total synthesis of Bistratamides H and J
- 14 January 2024
- Published by Elsevier in Tetrahedron Letters
- Vol. 136
Convenient total synthesis of Bistratamides H and J
- 22 December 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 265, 116066
Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme
- 22 December 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 265, 116066
Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme
- Open Access
- 18 September 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (10) , 1821-1833
Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development
Each year, approximately 50,000 children under 5 die as a result of diarrhea caused by Cryptosporidium parvum, a protozoan parasite. There are currently no effective drugs or vaccines available to cure or prevent Cryptosporidium infection, and there are limited tools for identifying and validating targets for drug or vaccine development. We previously reported a high throughput screening (HTS) of a large compound library against Plasmodium N-myristoyltransferase (NMT), a validated drug target in multiple protozoan parasite species. To identify molecules that could be effective against Cryptosporidium, we counter-screened hits from the Plasmodium NMT HTS against Cryptosporidium NMT. We identified two potential hit compounds and validated them against CpNMT to determine if NMT might be an attractive drug target also for Cryptosporidium. We tested the compounds against Cryptosporidium using both cell-based and NMT enzymatic assays. We then determined the crystal structure of CpNMT bound to Myristoyl-Coenzyme A (MyrCoA) and structures of ternary complexes with MyrCoA and the hit compounds to identify the ligand binding modes. The binding site architectures display different conformational states in the presence of the two inhibitors and provide a basis for rational design of selective inhibitors.
- 18 September 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 9 (10) , 1821-1833
Open AccessIdentification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development
Each year, approximately 50,000 children under 5 die as a result of diarrhea caused by Cryptosporidium parvum, a protozoan parasite. There are currently no effective drugs or vaccines available to cure or prevent Cryptosporidium infection, and there are limited tools for identifying and validating targets for drug or vaccine development. We previously reported a high throughput screening (HTS) of a large compound library against Plasmodium N-myristoyltransferase (NMT), a validated drug target in multiple protozoan parasite species. To identify molecules that could be effective against Cryptosporidium, we counter-screened hits from the Plasmodium NMT HTS against Cryptosporidium NMT. We identified two potential hit compounds and validated them against CpNMT to determine if NMT might be an attractive drug target also for Cryptosporidium. We tested the compounds against Cryptosporidium using both cell-based and NMT enzymatic assays. We then determined the crystal structure of CpNMT bound to Myristoyl-Coenzyme A (MyrCoA) and structures of ternary complexes with MyrCoA and the hit compounds to identify the ligand binding modes. The binding site architectures display different conformational states in the presence of the two inhibitors and provide a basis for rational design of selective inhibitors.
- 9 April 2021
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 53 (16) , 2874-2880
First Total Synthesis of 27-Deoxylyngbyabellin A
In this study, we document the first total synthesis of the marine cyanobacteria secondary metabolite 27-deoxylyngbyabellin A in 10 linear steps with 9.7% overall yield. Key steps entailed (1) one-pot cascade reaction of (S)-2-(benzyloxy)-3-methylbutanoic acid and of Boc-l-Ile-OH with a β-azido disulfide building block to access two critical thiazole units, (2) chiral oxazaborolidinone-mediated asymmetric aldol reaction to construct an (S)-β-hydroxy ester, and (3) diphenyl phosphorazidate mediated macrolactamization of the assembled linear precursor to achieve the natural product 27-deoxylyngbyabellin A.
- 9 April 2021
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 53 (16) , 2874-2880
First Total Synthesis of 27-Deoxylyngbyabellin A
In this study, we document the first total synthesis of the marine cyanobacteria secondary metabolite 27-deoxylyngbyabellin A in 10 linear steps with 9.7% overall yield. Key steps entailed (1) one-pot cascade reaction of (S)-2-(benzyloxy)-3-methylbutanoic acid and of Boc-l-Ile-OH with a β-azido disulfide building block to access two critical thiazole units, (2) chiral oxazaborolidinone-mediated asymmetric aldol reaction to construct an (S)-β-hydroxy ester, and (3) diphenyl phosphorazidate mediated macrolactamization of the assembled linear precursor to achieve the natural product 27-deoxylyngbyabellin A.